Oct 17 (Reuters) - ECKERT & ZIEGLER STRAHLEN UND
MEDIZINTECHNIK AG EUZG.DE :
* 9M PROFIT OF 20.3 MILLION EUR (PREVIOUS YEAR: 23.3 MILLION
EUR)
* OUTLOOK 2023: SALES OF JUST UNDER 230 MILLION EUR
(CONFIRMED)
* MAIN DRIVER OF THIS DEVELOPMENT IS CONTINUING DEMAND FOR
RADIOISOTOPES FOR PHARMACEUTICAL APPLICATIONS, WHICH LED TO
GROWTH OF AROUND 27% IN MEDICAL SEGMENT (DELETES REFERENCE TO
OUTLOOK)
* EQS-ADHOC: ECKERT & ZIEGLER ACHIEVES DOUBLE-DIGIT GROWTH
IN Q3
VERSUS PREVIOUS YEAR. SIGNIFICANT JUMP IN SALES ALSO IN FIRST 9
MONTHS, EARNINGS STILL BURDENED BY SPECIAL ITEMS COMPARED TO
SAME PERIOD LAST YEAR.
* MAIN DRIVERS OF DECLINE IN EARNINGS COMPARED TO PREVIOUS
YEAR
ARE CURRENCY EFFECTS AS WELL AS INFLATION ADJUSTMENTS IN
HYPERINFLATIONARY COUNTRY OF ARGENTINA (DELETES REFERENCE TO
OUTLOOK)
* Q3 SALES OF 65.9 MILLION EUR (PREVIOUS YEAR: 57.2 MILLION
EUR)
* OUTLOOK 2023: PROFIT OF AROUND EUR 25 MILLION (CONFIRMED)
* THESE AMOUNT TO AROUND 4.5 MILLION EUR (DELETES REFERENCE
TO
OUTLOOK)
* Q3 PROFIT OF 9.4 MILLION EUR (PREVIOUS YEAR: 7.9 MILLION
EUR)
Further company coverage: EUZG.DE
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))